Sandoz agrees to end three Crexont suits and Sandoz stock costs EUR 77.51

Published on 10/14/2026 at 12:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half 2026 sales rose 5 percent to USD 5.8 billion. Sandoz stock costs EUR 77.51 on October 14, 2026 in Germany.

Patent dispute and growth figures

Sandoz and Amneal agreed to dismiss three Crexont lawsuits on October 13, 2026.
First-half 2026 sales reached USD 5.8 billion, up 5 percent at constant currency.
Sandoz stock traded at EUR 77.51 at 12:37 p.m. CEST at Lang & Schwarz on October 14, 2026.

Sandoz, CH1243598427, Illustration mit AI erstellt.

Sandoz (ISIN CH1243598427) was trading at EUR 77.51 at Lang & Schwarz on October 14, 2026 at 12:37 p.m. CEST. The company and Amneal agreed on October 13, 2026 to dismiss three patent lawsuits involving proposed copies of Crexont, according to Bloomberg Law.

What changes after the patent dismissal?

The agreement concerns three cases filed in the United States over proposed generic versions of the Parkinson's treatment Crexont. The cases were dismissed without prejudice, meaning the court filings ended without a final ruling on the underlying claims, according to Bloomberg Law.

Growth remains concentrated in biosimilars

Sandoz reported first-half 2026 net sales of USD 5.8 billion, up 5 percent at constant currency from USD 5.2 billion a year earlier, according to S&P Global Ratings. Biosimilar sales increased 20 percent at constant currency, while the core EBITDA margin reached 20.9 percent, compared with 20.0 percent in first-half 2025.

The operating mix is the key investor issue: biosimilars accounted for 35 percent of first-half sales growth context through a 20 percent increase, while the top 10 medicines rose 14 percent at constant currency, according to S&P Global Ratings.

Three dated developments shape the story

On September 18, 2026, Sandoz announced Canadian authorization for generic semaglutide, with production capacity linked to close to 12 million injection pens annually, according to finanzen.ch.

On September 29, 2026, the company opened a high-volume biosimilar drug-substance facility in Lendava, Slovenia, staffed by more than 300 experts, according to Simply Wall St. The October 13 patent dismissal is the latest of the three developments and removes one legal dispute from the near-term product pipeline narrative.

Next reporting date and market context

finanzen.ch identifies February 17, 2027 as the expected publication date for Sandoz fourth-quarter 2026 figures, giving investors a clear next reporting milestone, according to finanzen.ch. Barclays maintained a Buy rating and a CHF 93.00 price target on October 12, 2026, according to Markets Insider.

At 12:37 p.m. CEST on October 14, 2026, Sandoz stock was trading at EUR 77.51 at Lang & Schwarz. The further course of trading is shown by the continuously updated real-time quote of Sandoz stock.